Key Points
-
Although large-scale genome-wide association studies have identified many rheumatic disease-associated genetic variants, effect sizes are small (with the exception of HLA loci)
-
Metabolomics is a promising field for investigating the molecular pathogenesis of rheumatic diseases and for monitoring response to therapy, but only a few modest-sized studies have been conducted to date
-
The contribution made by genetic factors to the production of metabolites and to disease processes in general needs to be investigated if metabolomics studies are to reach their full potential
-
Integrating data from different omics studies, including metagenomics and proteomics, will help to increase our knowledge of pathways and diseases
Abstract
Metabolomics is an exciting field in systems biology that provides a direct readout of the biochemical activities taking place within an individual at a particular point in time. Metabolite levels are influenced by many factors, including disease status, environment, medications, diet and, importantly, genetics. Thanks to their dynamic nature, metabolites are useful for diagnosis and prognosis, as well as for predicting and monitoring the efficacy of treatments. At the same time, the strong links between an individual's metabolic and genetic profiles enable the investigation of pathways that underlie changes in metabolite levels. Thus, for the field of metabolomics to yield its full potential, researchers need to take into account the genetic factors underlying the production of metabolites, and the potential role of these metabolites in disease processes. In this Review, the methodological aspects related to metabolomic profiling and any potential links between metabolomics and the genetics of some of the most common rheumatic diseases are described. Links between metabolomics, genetics and emerging fields such as the gut microbiome and proteomics are also discussed.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nicholson, J. K. & Lindon, J. C. Systems biology: metabonomics. Nature 455, 1054–1056 (2008).
Tektonidou, M. G. & Ward, M. M. Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. Arthritis Res. Ther. 12, R179 (2010).
Kapoor, S. R. et al. Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum. 65, 1448–1456 (2013).
Suhre, K. et al. A genome-wide association study of metabolic traits in human urine. Nat. Genet. 43, 565–569 (2011).
Suhre, K. et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54–60 (2011).
Illig, T. et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 42, 137–141 (2010).
Shin, S. Y. et al. An atlas of genetic influences on human blood metabolites. Nat. Genet. 46, 543–550 (2014).
Rhee, E. P. et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab. 18, 130–143 (2013).
Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44, 269–276 (2012).
Wishart, D. S. et al. HMDB 3.0 — the Human Metabolome Database in 2013. Nucleic Acids Res. 41, D801–D807 (2013).
Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872–881 (2012).
Larive, C. K., Barding, G. A. Jr & Dinges, M. M. NMR spectroscopy for metabolomics and metabolic profiling. Anal. Chem. 87, 133–146 (2015).
Patti, G. J., Yanes, O. & Siuzdak, G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell. Biol. 13, 263–269 (2012).
Lewis, G. D., Asnani, A. & Gerszten, R. E. Application of metabolomics to cardiovascular biomarker and pathway discovery. J. Am. Coll. Cardiol. 52, 117–123 (2008).
Armstrong, A. W. et al. Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. F1000Res. 3, 248 (2014).
Zabek, A. et al. Application of 1H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis. J. Pharm. Biomed. Anal. 117, 544–550 (2016).
Loeser, R. F. et al. Association of urinary metabolites with radiographic progression of knee osteoarthritis in overweight and obese adults: an exploratory study. Osteoarthritis Cartilage 24, 1479–1486 (2016).
Zhang, W. et al. Metabolomic analysis of human plasma reveals that arginine is depleted in knee osteoarthritis patients. Osteoarthritis Cartilage 24, 827–834 (2016).
Menni, C. et al. Metabolomic identification of a novel pathway of blood pressure regulation involving hexadecanedioate. Hypertension 66, 422–429 (2015).
Menni, C. et al. Circulating levels of antioxidant vitamins correlate with better lung function and reduced exposure to ambient pollution. Am. J. Respir. Crit. Care Med. 191, 1203–1207 (2015).
Krumsiek, J. et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet. 8, e1003005 (2012).
Malet-Martino, M. & Holzgrabe, U. NMR techniques in biomedical and pharmaceutical analysis. J. Pharm. Biomed. Anal. 55, 1–15 (2011).
Griffiths, W. J. et al. Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed. 49, 5426–5445 (2010).
Koal, T. & Deigner, H. P. Challenges in mass spectrometry based targeted metabolomics. Curr. Mol. Med. 10, 216–226 (2010).
Guma, M., Tiziani, S. & Firestein, G. S. Metabolomics in rheumatic diseases: desperately seeking biomarkers. Nat. Rev. Rheumatol. 12, 269–281 (2016).
Marion, D. An introduction to biological NMR spectroscopy. Mol. Cell. Proteomics 12, 3006–3025 (2013).
Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192–206 (2015).
Markley, J. L. et al. The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 43, 34–40 (2016).
Fan, T. W. & Lane, A. N. Applications of NMR spectroscopy to systems biochemistry. Prog. Nucl. Magn. Reson. Spectrosc. 92–93, 18–53 (2016).
Lei, Z., Huhman, D. V. & Sumner, L. W. Mass spectrometry strategies in metabolomics. J. Biol. Chem. 286, 25435–25442 (2011).
Feng, X., Liu, X., Luo, Q. & Liu, B. F. Mass spectrometry in systems biology: an overview. Mass Spectrom. Rev. 27, 635–660 (2008).
Kind, T. et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 81, 10038–10048 (2009).
Sellick, C. A. et al. Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells: matching extraction approaches to cell type and metabolite targets. Metabolomics 6, 427–438 (2010).
Xi, B., Gu, H., Baniasadi, H. & Raftery, D. Statistical analysis and modeling of mass spectrometry-based metabolomics data. Methods Mol. Biol. 1198, 333–353 (2014).
Madsen, R., Lundstedt, T. & Trygg, J. Chemometrics in metabolomics — a review in human disease diagnosis. Anal. Chim. Acta 659, 23–33 (2010).
Nikolic, S. B., Sharman, J. E., Adams, M. J. & Edwards, L. M. Metabolomics in hypertension. J. Hypertens. 32, 1159–1169 (2014).
Manoli, T. et al. Group testing for pathway analysis improves comparability of different microarray datasets. Bioinformatics 22, 2500–2506 (2006).
Draghici, S., Khatri, P., Martins, R. P., Ostermeier, G. C. & Krawetz, S. A. Global functional profiling of gene expression. Genomics 81, 98–104 (2003).
Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
Kramer, A., Green, J., Pollard, J. Jr & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523–530 (2014).
Wheeler, D. L. et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 36, D13–D21 (2008).
Kanehisa, M. et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354–D357 (2006).
Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 44, D471–D480 (2016).
Hastings, J. et al. ChEBI in 2016: improved services and an expanding collection of metabolites. Nucleic Acids Res. 44, D1214–D1219 (2016).
Kale, N. S. et al. MetaboLights: an open-access database repository for metabolomics data. Curr. Protoc. Bioinformatics http://dx.doi.org/10.1002/0471250953.bi1413s53 (2016).
Yan, B. et al. Urinary metabolomic study of systemic lupus erythematosus based on gas chromatography/mass spectrometry. Biomed. Chromatogr. 30, 1877–1881 (2016).
Madsen, R. K. et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res. Ther. 13, R19 (2011).
Zhai, G. et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann. Rheum. Dis. 69, 1227–1231 (2010).
Young, S. P. et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 65, 2015–2023 (2013).
Wu, T. et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS ONE 7, e37210 (2012).
Perl, A. et al. Comprehensive metabolome analyses reveal -acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 11, 1157–1174 (2015).
Kamleh, M. A. et al. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFalpha treatment. J. Proteome Res. 14, 557–566 (2015).
Priori, R. et al. 1H-NMR-based metabolomic study for identifying serum profiles associated with the response to etanercept in patients with rheumatoid arthritis. PLoS ONE 10, e0138537 (2015).
Schmidt, M. et al. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum. 60, 2913–2922 (2009).
Jiang, M. et al. Serum metabolic signatures of four types of human arthritis. J. Proteome Res. 12, 3769–3779 (2013).
Zeggini, E. et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet 380, 815–823 (2012).
Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).
Yin, X. et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat. Commun. 6, 6916 (2015).
Yang, W. et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am. J. Hum. Genet. 92, 41–51 (2013).
Michaud, K. & Wolfe, F. Comorbidities in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21, 885–906 (2007).
Vande Walle, L. et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512, 69–73 (2014).
Lee, H. S. et al. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 66, 863–873 (2014).
Kamekura, S. et al. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum. 54, 2462–2470 (2006).
Schminke, B., Trautmann, S., Mai, B., Miosge, N. & Blaschke, S. Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage. Eur. J. Immunol. 46, 440–445 (2016).
Adamski, J. Genome-wide association studies with metabolomics. Genome Med. 4, 34 (2012).
Conigliaro, P. et al. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 15, 673–683 (2016).
Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89–R98 (2014).
Smith, G. D. & Ebrahim, S. Mendelian randomization: prospects, potentials, and limitations. Int. J. Epidemiol. 33, 30–42 (2004).
Vuckovic, F. et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 67, 2978–2989 (2015).
Stahl, E. A. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat. Genet. 44, 483–489 (2012).
Evangelou, E. et al. A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Ann. Rheum. Dis. 73, 2130–2136 (2014).
Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
Lin, P. et al. HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PLoS ONE 9, e105684 (2014).
Vellucci, R. Heterogeneity of chronic pain. Clin. Drug Invest. 32 (Suppl. 1), 3–10 (2012).
Lamers, R. J. et al. Identification of an urinary metabolite profile associated with osteoarthritis. Osteoarthritis Cartilage 13, 762–768 (2005).
Mickiewicz, B. et al. Metabolic analysis of knee synovial fluid as a potential diagnostic approach for osteoarthritis. J. Orthop. Res. 33, 1631–1638 (2015).
Zhou, J. et al. Exploration of the serum metabolite signature in patients with rheumatoid arthritis using gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 127, 60–67 (2016).
Ouyang, X., Dai, Y., Wen, J. L. & Wang, L. X. 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. Lupus 20, 1411–1420 (2011).
Yan, B. et al. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS. Mod. Rheumatol. 26, 914–922 (2016).
Sitter, B., Johnsson, M. K., Halgunset, J. & Bathen, T. F. Metabolic changes in psoriatic skin under topical corticosteroid treatment. BMC Dermatol. 13, 8 (2013).
Liu, Y. et al. A metabolic profiling analysis of symptomatic gout in human serum and urine using high performance liquid chromatography-diode array detector technique. Clin. Chim. Acta 412, 2132–2140 (2011).
Albrecht, E. et al. Metabolite profiling reveals new insights into the regulation of serum urate in humans. Metabolomics 10, 141–151 (2014).
Acknowledgements
TwinsUK was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. T.D.S. is an NIHR Senior Investigator and is holder of a European Research Council Advanced Principal Investigator award. The work of C.M., A.M.V. and T.D.S. is supported by a grant from the Medical Research Council AimHY programme (MR/M016560/1). The work of A.M.V. was supported by a grant from the Arthritis Research UK Pain Centre (18769).
Author information
Authors and Affiliations
Contributions
C.M., J.Z. and A.M.V. researched the data for the article. C.M. and A.M.V. wrote the article. All authors provided a substantial contribution to discussions of the content and contributed equally to review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Examples of metabolomics studies investigating rheumatic diseases. (PDF 231 kb)
Supplementary information S1 (figure)
Genetic basis of rheumatic diseases. (PDF 849 kb)
Rights and permissions
About this article
Cite this article
Menni, C., Zierer, J., Valdes, A. et al. Mixing omics: combining genetics and metabolomics to study rheumatic diseases. Nat Rev Rheumatol 13, 174–181 (2017). https://doi.org/10.1038/nrrheum.2017.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.5
This article is cited by
-
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective
Nature Medicine (2023)
-
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Nature Reviews Rheumatology (2022)
-
Metabolomic profiles of induced pluripotent stem cells derived from patients with rheumatoid arthritis and osteoarthritis
Stem Cell Research & Therapy (2019)
-
NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker
Journal of Translational Medicine (2018)
-
Expression and Metabolomic Profiling in Axial Spondyloarthritis
Current Rheumatology Reports (2018)